Rajesh Devraj
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Synthesis and biological activity, Chemical Synthesis and Analysis, Synthesis and Characterization of Heterocyclic Compounds, Quinazolinone synthesis and applications
Most-Cited Works
- → Physiochemical drug properties associated with in vivo toxicological outcomes(2008)954 cited
- → Chemical Library Purification Strategies Based on Principles of Complementary Molecular Reactivity and Molecular Recognition(1997)211 cited
- → Small Molecule SARM1 Inhibitors Recapitulate the SARM1−/− Phenotype and Allow Recovery of a Metastable Pool of Axons Fated to Degenerate(2021)184 cited
- → Pharmacological SARM1 inhibition protects axon structure and function in paclitaxel-induced peripheral neuropathy(2021)144 cited
- → Axons Matter: The Promise of Treating Neurodegenerative Disorders by Targeting SARM1-Mediated Axonal Degeneration(2020)130 cited
- → cADPR is a gene dosage-sensitive biomarker of SARM1 activity in healthy, compromised, and degenerating axons(2020)124 cited
- → Solution-phase chemical library synthesis using polymerassisted purification techniques(1999)91 cited
- → Discovery of PH-797804, a highly selective and potent inhibitor of p38 MAP kinase(2011)71 cited
- → Classical and Nonclassical Furo[2,3-d]pyrimidines as Novel Antifolates: Synthesis and Biological Activities(1994)70 cited
- → Synthesis, Crystal Structure, and Activity of Pyrazole-Based Inhibitors of p38 Kinase(2007)64 cited